Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

医学 2型糖尿病 肾脏疾病 糖尿病 临床终点 内科学 随机对照试验 重症监护医学 内分泌学
作者
Hiddo J.L. Heerspink,Andreas L. Birkenfeld,David Z.I. Cherney,Helen M. Colhoun,Linong Ji,Chantal Mathieu,Per‐Henrik Groop,Richard E. Pratley,Sylvia E. Rosas,Peter Rossing,Jay S. Skyler,Katherine R. Tuttle,Robert Lawatscheck,Charlie Scott,Robert Edfors,Markus F. Scheerer,Peter Kolkhof,Janet B. McGill
出处
期刊:Diabetes Research and Clinical Practice [Elsevier]
卷期号:204: 110908-110908 被引量:9
标识
DOI:10.1016/j.diabres.2023.110908
摘要

Despite guideline-recommended treatments, including renin angiotensin system inhibition, up to 40 % of individuals with type 1 diabetes develop chronic kidney disease (CKD) putting them at risk of kidney failure. Finerenone is approved to reduce the risk of kidney failure in individuals with type 2 diabetes. We postulate that finerenone will demonstrate benefits on kidney outcomes in people with type 1 diabetes.FINE-ONE (NCT05901831) is a randomised, placebo-controlled, double-blind phase III trial of 7.5 months' duration in ∼220 adults with type 1 diabetes, urine albumin/creatinine ratio (UACR) of ≥ 200-< 5000 mg/g (≥ 22.6-< 565 mg/mmol) and eGFR of ≥ 25-< 90 ml/min/1.73 m2.The primary endpoint is relative change in UACR from baseline over 6 months. UACR is used as a bridging biomarker (BB), since the treatment effect of finerenone on UACR was associated with its efficacy on kidney outcomes in the type 2 diabetes trials. Based on regulatory authority feedback, UACR can be used as a BB for kidney outcomes to support registration of finerenone in type 1 diabetes, provided necessary criteria are met. Secondary outcomes include incidences of treatment-emergent adverse events, treatment-emergent serious adverse events and hyperkalaemia.FINE-ONE will evaluate the efficacy and safety of finerenone in type 1 diabetes and CKD. Finerenone could become the first registered treatment for CKD associated with type 1 diabetes in almost 30 years.ClinicalTrials.gov NCT05901831.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
顺利兰完成签到 ,获得积分10
1秒前
木子草甜完成签到,获得积分10
2秒前
2秒前
眼睛大的剑心完成签到 ,获得积分10
2秒前
高贵黄蜂发布了新的文献求助10
2秒前
香蕉觅云应助泽锦臻采纳,获得10
3秒前
4秒前
年轻子骞完成签到,获得积分10
4秒前
John完成签到,获得积分20
4秒前
ggg完成签到,获得积分10
4秒前
野草发布了新的文献求助10
4秒前
李爱国应助HM采纳,获得10
5秒前
5秒前
Orange应助mxt采纳,获得10
5秒前
如初完成签到,获得积分10
5秒前
小张完成签到,获得积分10
6秒前
shy完成签到,获得积分10
6秒前
6秒前
6秒前
好心情发布了新的文献求助10
7秒前
7秒前
7秒前
lzl007完成签到 ,获得积分10
8秒前
jason0023发布了新的文献求助10
8秒前
lqm发布了新的文献求助10
9秒前
10秒前
AKLIZE完成签到,获得积分10
11秒前
11秒前
zzt完成签到 ,获得积分10
11秒前
mmyhn应助星夜港湾采纳,获得10
11秒前
HDUTY发布了新的文献求助10
12秒前
chenpsy完成签到,获得积分10
12秒前
12秒前
lyp完成签到 ,获得积分10
12秒前
方赫然发布了新的文献求助10
12秒前
无奈醉柳完成签到 ,获得积分10
12秒前
酷波er应助称心不尤采纳,获得10
12秒前
大鱼完成签到 ,获得积分10
13秒前
15秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 720
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3567156
求助须知:如何正确求助?哪些是违规求助? 3139675
关于积分的说明 9432949
捐赠科研通 2840458
什么是DOI,文献DOI怎么找? 1561046
邀请新用户注册赠送积分活动 730189
科研通“疑难数据库(出版商)”最低求助积分说明 717869